Hims & Hers Health Inc. (HIMS) is having a rough Monday. The telehealth company announced plans to offer $300 million in convertible senior notes due 2032 through a private placement, and investors are not thrilled. Shares were down about 8% at $23.02 at the time of publication.
The capital raise has likely intensified concerns about dilution and increased leverage, adding pressure to what was already a multi-session slide. The stock has lost about 63% over the past year, so this isn't a new problem — but the offering is a fresh reminder of the risks.
What's the Money For?
Hims & Hers said it plans to use the proceeds to maintain financial flexibility while pushing ahead with its international growth strategy. That includes funding the proposed acquisition of Eucalyptus, which is expected to close in mid-2026. The company also wants to invest in technology and fulfillment infrastructure to improve operational efficiency, and expand its artificial intelligence capabilities to enhance the consumer experience and strengthen its closed-loop data ecosystem.
Additionally, a portion of the proceeds will fund capped call transactions tied to the notes. These are designed to reduce potential dilution to the company's Class A common stock if the notes are converted. It's a common move — think of it as a hedge against dilution — but it doesn't fully erase investor worries.
The Fine Print on the Notes
The notes are senior unsecured obligations that accrue semi-annual interest and mature on June 1, 2032, unless earlier repurchased, redeemed, or converted. Holders can convert them under certain conditions, and Hims & Hers can choose to settle conversions with cash, shares of Class A common stock, or a mix of both.
The company also has the option to redeem the notes for cash starting June 6, 2029, but only if its stock price exceeds 130% of the conversion price for a defined period. That's a pretty high bar given the stock's recent performance, but it gives the company some flexibility down the road.
Investors are also getting an option: initial purchasers can buy up to an additional $45 million in notes within 13 days of issuance. That's a standard feature, but it adds to the overall size of the offering.
The Bottom Line
Hims & Hers is making a big bet on growth — international expansion, AI, and infrastructure — but it's asking investors to swallow potential dilution in return. The market's reaction suggests skepticism, at least for now. Whether the strategy pays off will depend on how well the company executes and whether the Eucalyptus acquisition delivers the global reach it promises.
